OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

Company Published White Paper titled, "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)" White Paper Unveils Ability to Directly Deliver Plasmid-Based IL-12 to Pancreatic, Liver a... Biopharmaceuticals, Oncology, Drug Delivery OncoSec Medical, Visceral Lesion Applicator, intratumoral, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 22 June 2019Source: Research in Veterinary ScienceAuthor(s): Marta Baxarias, Pamela Martínez-Orellana, Gad Baneth, Laia Solano-GallegoAbstractLeishmaniosis due to Leishmania infantum is a complex infection that can affect both humans and dogs, and present a wide range of clinical signs and clinicopathological abnormalities. The conventional treatment of this disease is challenging due to the fact that complete parasitological cure commonly does not occur. Furthermore, treatment of the disease with the conventionally used drugs has several shortcomings. These include the need for lo...
Source: Research in Veterinary Science - Category: Veterinary Research Source Type: research
This study focuses on long-term survival after curative resection for pancreatic adenocarcinoma. The goal of this study was to explore the role of immunotherapy given in adjuvant settings in combination with chemotherapy, as compared with chemotherapy alone. Using the National Cancer Database (NCDB), the authors identified 21,313 patients who received adjuvant therapy after curative resection for pancreatic cancer between 2004 and 2015. Propensity score matching was used to develop 2 comparable cohorts of patients who received a combination of chemotherapy and immunotherapy and those who got chemotherapy alone.
Source: Journal of the American College of Surgeons - Category: Surgery Tags: Western surgical association article Source Type: research
(University of Colorado Anschutz Medical Campus) Colorado study shows that adding HDAC inhibitor sensitized cancers to anti-PD1 therapy.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell responses. These immunogenic mutated peptides, or neoantigens, are foreign in nature and display exquisite tumor specificity. The correlative evidence suggesting they play an important role in the effectiveness of various cancer immunotherapies has triggered the development of vaccines and adoptive T-cell therapies targeting them. However, the systematic identification of personalized neoantigens in cancer patients, a critical requisite for the success o...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This case report highlights that multidisciplinary treatment planning is critical for stage IIIb –IV non‐small cell lung cancer (NSCLC) patients in the era of highly effective treatments, including chemotherapy, molecular targeted therapy, and immunotherapy, which may demonstrate treatment‐free remission (TFR) even in highly selected advanced lung cancer patients with poly‐metastases, a nd we need more information about the association between each genetic alteration and the significance of salvage surgery. The prognosis of stage IVb non ‐small cell lung cancer (NSCLC) patients with multiple distant metastase...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
This study summarizes the recent advances in our understanding of the sources, the anticancer mechanism, and the biosynthetic pathway of paclitaxel. With the advancement of biotechnology, improvements in endophytic fungal strains, and the use of recombination techniques and microbial fermentation engineering, the yield of extracted paclitaxel has increased significantly. Recently, paclitaxel has been found to play a large role in tumor immunity, and it has a great potential for use in many cancer treatments. PMID: 31223315 [PubMed - in process]
Source: Cellular and Molecular Biology Letters - Category: Biochemistry Authors: Tags: Cell Mol Biol Lett Source Type: research
Authors: Banach M, Robert J Abstract Cancers impose a significant health and economic burden. By harnessing the immune system, current immunotherapies have revolutionized the treatment against human cancers and potentially offer a long-term cure. Among others, innate-like T (iT) cells, including natural killer T cells, are promising candidates for immunotherapies. Unlike conventional T cells, iT cells regulate multiple immune processes and express an invariant T cell receptor that is shared among different individuals. However, the conditions that activate the pro- and antitumor functions of iT cells are partially ...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Authors: Miranda J, Viñal D, Pinto Á Abstract The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the recent years with the approval of several new drugs. Together with other treatment modalities including chemotherapy, hormonal therapy and immunotherapy, radiopharmaceuticals have recently been incorporated to the therapeutic scenario of prostate cancer with the approval of Radium 223 dichloride (Ra-223) for the treatment of mCRPC patients with symptomatic bone metastasis and no visceral metastases. Radiopharmaceuticals have long been used...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
CONCLUSIONS: Several similar case reports reported in literature show an increasing rate of toxicities from immunotherapy in this setting. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice. PMID: 31221037 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
AbstractPQ Grass represents an allergen ‐specific immunotherapy for pre‐seasonal treatment of patients with seasonal allergic rhinitis (or rhinoconjunctivitis) with or without mild‐to‐moderate bronchial asthma. It consists of a native pollen extract for 13 grass species, chemically modified with glutaraldehyde, and adsorbed tol‐tyrosine in a microcrystalline form with addition of the adjuvant Monophosphoryl Lipid A (MPL®). Previous non ‐clinical safety testing, including rat repeat dose toxicity in adult and juvenile animals, rat reproductive toxicity and rabbit local tolerance studies showed no safety find...
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
More News: Cancer & Oncology | Immunotherapy | Liver | Pancreas | Pharmaceuticals | Urology & Nephrology